Status: Not yet recruiting
CS1 Added to Standard of Care Therapy for Pulmonary Arterial Hypertension
This Phase 2 study (EPIMODE) will evaluate the efficacy and safety of CS1 compared with placebo when added to standard-of-care therapy in participants with pulmonary arterial hypertension. Participants completing Treatment Period 1 (Week 36) will be re-randomized to continue or switch study treatment for Treatment Period 2 through Week 52.
Participants needed: 126
Trial details
Phase: Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: Cereno Scientific ABUpdated: Aug 12, 2026
Eligibility criteria
Age 18 to 80 years [+6]
Pulmonary hypertension WHO Group 2, 3, 4, or 5 [+6]